Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

28.00 -1.34 (-4.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 594,512
Open 27.91
Bid (Size) 27.50 (2)
Ask (Size) 29.04 (1)
Prev. Close 29.34
Today's Range 27.81 - 28.17
52wk Range 26.32 - 42.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire

Performance

YTD
-12.80%
-12.80%
1 Month
-1.65%
-1.65%
3 Month
-3.98%
-3.98%
6 Month
-11.45%
-11.45%
1 Year
-27.74%
-27.74%

More News

Read More
Genmab Completes Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
What 9 Analyst Ratings Have To Say About Genmab
Via Benzinga
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Decoding 9 Analyst Evaluations For Genmab
Via Benzinga
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
NASDAQ:GMAB is not too expensive for the growth it is showing.
Via Chartmill
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Analyst Ratings For Genmab
Via Benzinga
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
Via Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
4 Analysts Assess Genmab: What You Need To Know
Via Benzinga
Earnings Outlook For Genmab
Via Benzinga
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
Via Investor's Business Daily
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.